Lummy gains Chinese rights to Argos' AGS-003

Argos Therapeutics Inc. (NASDAQ:ARGS) granted the Lummy Co. Ltd. subsidiary of Chongqing Lummy Pharmaceutical Co. Ltd. (SZSE:300006) development and commercialization rights in greater China for AGS-003 in oncology indications.

Argos is conducting a Phase III study of the second-generation RNA-loaded autologous dendritic cell immunotherapy to treat metastatic renal cell carcinoma (mRCC). Lummy said it may develop AGS-003 to treat pancreatic, lung, liver, stomach, rectal, gastric and/or esophageal cancers. ...